Search

Pfizer

Atidarymo kaina

SektoriusSveikatos priežiūra

27.79 0.04

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

27.57

Max

27.94

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-2.9B

-238M

Pardavimai

583M

15B

P/E

Sektoriaus vid.

37.434

56.597

Pelnas, tenkantis vienai akcijai

0.77

Dividendų pajamingumas

5.97

Pelno marža

-1.583

Darbuotojai

75,000

EBITDA

-3.8B

1.2B

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+2.41% upside

Dividendai

By Acuity

Dividendų pajamingumas

Sektoriaus vid.

5.97%

2.18%

Kitas uždarbis

2026-11-03

Kita Ex Dividend data

2026-11-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

19B

162B

Ankstesnė atidarymo kaina

27.75

Ankstesnė uždarymo kaina

27.79

Naujienos nuotaikos

By Acuity

48%

52%

127 / 339 reitingas Healthcare

Pfizer Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-09-08 20:08; UTC

News
Social Media

Pfizer shares are lower as the company announces a webcast featuring CEO Albert Bourla at the Morgan Stanley Healthcare Conference scheduled for September 2026.

2026-09-04 23:05; UTC

Pfizer Inc shares are lower in after-market hours, reflecting a slight decline since Friday's close amid mixed economic signals affecting market sentiment.

2026-09-03 23:01; UTC

Pfizer Inc. shares are lower in after-market hours, following a weak trading session and amid broader market softness from recent economic data on jobless claims.

2026-09-02 23:06; UTC

Pfizer Inc. shares are lower in after-market hours, amid a weaker ADP payrolls report signaling potential labor market weakness affecting future Federal Reserve policy.

2026-09-01 20:09; UTC

News

Pfizer Inc shares reached a 22-month high of $28.86 today, driven by a significant upward trend in the Pharmaceuticals sub-sector amid overall market gains.

2026-08-31 23:06; UTC

Pfizer Inc shares rose in after-hours trading, holding above the 20-day moving average and near the upper end of their one-month range.

2026-08-28 23:01; UTC

Pfizer Inc. shares are lower in after-market trading, continuing a trend from the previous three sessions. No specific news was identified to explain the decline.

2026-08-27 23:02; UTC

Social Media
News

Pfizer and BioNTech received FDA approval for their XFG-adapted COVID-19 vaccine, COMIRNATY XFG, boosting shares in after-market trading.

2026-08-26 23:06; UTC

Pfizer Inc shares are lower in after-market hours amid notable volatility. Broader market weakness and a stronger U.S. Dollar Index contributed to the decline.

2026-08-25 23:06; UTC

Pfizer Inc. shares are lower in after-market trading, reflecting weaker sentiment amid broader market declines linked to falling crude oil prices.

2026-08-24 19:36; UTC

Pfizer Inc. shares are lower today, continuing a decline since Friday's close. The stock remains above its 20-day moving average.

2026-08-21 23:01; UTC

Pfizer Inc shares are lower in after-market trading, reflecting a downward trend amid broader market volatility related to inflation and government debt concerns.

2026-08-20 19:41; UTC

Pfizer Inc's shares are lower today amid a broader downturn in the Pharmaceuticals sub-sector, marking a shift from recent gains.

2026-08-19 23:51; UTC

Pfizer Inc shares are lower in after-market hours, reversing gains from three consecutive sessions. No specific news was identified to explain the price action.

2026-08-18 19:16; UTC

Social Media
Event

Pfizer reported second-quarter adjusted EPS of $0.77, exceeding estimates, and raised its sales outlook for fiscal year 2026, with shares trading higher.

2026-08-17 23:36; UTC

Event

Pfizer Inc shares are lower in after-market hours following the announcement of Xtandi's new indication for prostate cancer treatment. The broader market also declined.

2026-08-14 23:51; UTC

Pfizer Inc. shares are higher in after-market hours amid broader economic concerns following a reported decline in U.S. retail sales for July.

2026-08-13 23:16; UTC

Pfizer Inc shares are lower in after-market hours following a decline from earlier gains. No specific news was identified to explain the movement.

2026-08-12 23:02; UTC

Social Media
News

Pfizer shares rose after Chairman Albert Bourla bought 38,000 shares at $26.34, totaling about $1 million, signaling confidence in the company's prospects.

2026-08-11 19:26; UTC

News

Pfizer Inc. shares are lower amid a $44 million settlement over its Chantix drug, which allegedly contained a cancer-linked substance.

2026-08-10 23:01; UTC

Pfizer Inc. shares are lower in after-market hours, continuing a decline since Monday's close amid rising Treasury yields and inflation concerns.

2026-08-08 00:02; UTC

Pfizer Inc shares are lower in after-market hours with no specific news identified. Broader market concerns about interest rate hikes continue to influence sentiment.

2026-08-07 23:01; UTC

Pfizer Inc shares are lower in after-market hours, reaching a session low earlier. No specific news was identified to explain the decline.

2026-08-06 23:51; UTC

Pfizer Inc shares are lower in after-market hours. The decline follows increased crude oil prices and a strengthening U.S. dollar, contributing to market volatility.

2026-08-05 23:02; UTC

Pfizer Inc shares are modestly higher in after-market hours, reaching a session high before pulling back slightly. No specific news was identified for the movement.

2026-08-04 23:21; UTC

Pfizer Inc shares are lower in after-market hours, with no specific news identified for the decline. Broader market sentiment remains positive amid falling crude oil prices.

2026-08-03 23:46; UTC

Social Media

Pfizer Inc shares are higher in after-market trading ahead of earnings. The stock remains above its 20-day moving average, reflecting positive market sentiment.

2026-07-31 23:06; UTC

Pfizer Inc shares are higher in after-market hours, reflecting slight gains since Friday's close. The stock remains near the upper end of its one-month range.

2026-07-30 23:26; UTC

Event

Pfizer shares are higher in after-market trading following Phase 3 trial results for LITFULO in nonsegmental vitiligo, despite three prior sessions of lower closes.

2026-07-29 23:16; UTC

News

Pfizer and BioNTech received European Commission approval for their XFG-adapted COVID-19 vaccine, valid across all EU member states. Shares are trading roughly flat after-market.

Akcijų palyginimas

Kainos pokytis

Pfizer Prognozė

Kainos tikslas

By TipRanks

2.41% į viršų

12 mėnesių prognozė

Vidutinis 28.46 USD  2.41%

Aukščiausias 35.75 USD

Žemiausias 25 USD

Remiantis 21 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Pfizer kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

21 ratings

7

Pirkti

13

Laikyti

1

Parduoti

Rinkos nuotaikos

By Acuity

127 / 339 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
help-icon Live chat